Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that revolutionized diabetes and weight loss did not slow the disease’s ...
(CNN) — An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk ...
While the drug was safe and improved some biological markers linked to the disease, it did not slow memory or cognitive decline compared to a placebo. HealthDay News — A pill version of semaglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results